With these downloadable slides presented at our symposium held at the 1st European Myeloma Network Meeting 2018, explore the latest updates on the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) with a focus on immunotherapy along with treatment selection and sequencing in the R/R disease setting.
Apr 23, 2018
Apr 23, 2019
- Pieter Sonneveld, MD, PhD, on behalf of Gareth Morgan, MD, PhD, FRCP, FRCPath, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Hot topic in MM: The evolving role for immunotherapy in patients with R/R disease
- Hermann Einsele, MD, Julius Maximilian University of Würzburg, Würzburg, Germany
Weighing the options at first relapse
- Meletios Dimopoulos, MD, University of Athens, Athens, Greece
How do I choose? Treatment decisions after multiple lines of therapy
- Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
After successful completion of this educational activity, participants should be able to:
- Discuss the rationale and mechanism of action for emerging immunotherapy options in the treatment of R/R MM
- Evaluate recent clinical trial data investigating the efficacy and safety of novel doublet and triplet treatment regimens and employ best practices in the selection of these regimens in the treatment of R/R MM
- Describe the factors that influence treatment selection and sequencing in the R/R disease setting
- Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM
This activity is intended for hematologists, oncologists, and other healthcare professionals involved in the management of patients with MM.
This educational activity is supported by a grant from Bristol-Myers Squibb.
ENDURING MATERIAL FROM A CERTIFIED ACTIVITY
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Dimopoulos has disclosed he has received honoraria or consultation fees from Amgen, Celgene, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Einsele has disclosed that he has received fees for grants/research support, honoraria or consultation fees, and advisory board participation from Amgen, Bristol-Myers Squibb, Celgene, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Morgan has no relevant financial relationship to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Sonneveld has disclosed that he has received grants/research support from Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He also disclosed that he has received honoraria or consultation fees from Amgen, Celgene, Janssen, Karyopharm, and Takeda. Dr Sonneveld participated in advisory boards for Amgen, Celgene, Janssen, Karyopharm, Skyline Dx, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.